Adverum Biotechnologies Inc (ADVM) is a clinical-stage gene therapy company that is focused on the development of treatments for rare diseases that affect the eyes and other organs. The company's lead product candidate, ADVM-022, is a one-time gene therapy designed to treat wet age-related macular degeneration (wet AMD), a progressive eye disease that can cause vision loss. The therapy delivers a gene that produces a protein that can inhibit the growth of new blood vessels in the eye, which can lead to the formation of abnormal blood vessels and damage to the retina.
Adverum's second product candidate, ADVM-043, is a gene therapy designed to treat hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. ADVM-043 delivers a gene that produces a protein that can inhibit the activity of a protein that is involved in the development of HAE.
Adverum's gene therapies are based on a proprietary platform technology called vectorization, which uses a proprietary viral vector to deliver genes to target cells. The company believes that its vectorization technology can provide a safe and effective way to deliver gene therapies to patients with rare diseases.
Adverum was founded in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies Inc (ADVM) is a clinical-stage gene therapy company that is focused on the development of treatments for rare diseases that affect the eyes and other organs. The company's lead product candidate, ADVM-022, is a one-time gene therapy designed to treat wet age-related macular degeneration (wet AMD), a progressive eye disease that can cause vision loss. The therapy delivers a gene that produces a protein that can inhibit the growth of new blood vessels in the eye, which can lead to the formation of abnormal blood vessels and damage to the retina.